Aurobindo Pharma shares rise nearly 3% to hit 52-week high as Q1 net profit rises 61% YoY

In a filing to the stock exchanges on Saturday, the pharma company said that its consolidated revenue from operations increased by 10.5% year-on-year to ₹7,567 crore in the June quarter compared to ₹6,851 crore a year ago.

Its net profit (after share of profit/loss of joint venture and minority interest) stood at ₹919 crore in Q1FY25, up 61.1% compared to ₹571 crore in Q1FY24.

At the operating level, earnings before interest, tax, depreciation and amortisation (EBITDA) before forex and other income rose 40.7% to ₹1,620 crore in the June quarter compared with ₹1,151 crore in the year-ago quarter. EBITDA margins also improved to 21.4% in Q1FY25 from 16.8% in Q1FY24.

The Hyderabad-based pharma company also announced that it has received final approval for 10 ANDAs (abbreviated new drug applications) during the quarter from the US Food and Drug Administration (USFDA).

Commenting on the earnings, Aurobindo Pharma’s vice-chairman and managing director, K. Nithyananda Reddy, said: “We are pleased with our continued strong performance this quarter, with significant top-line growth across all our business segments. Our profitability was sustained by improved gross margins and operational efficiencies while ramping up our recently commercialized plants. We are confident in our ability to achieve our growth targets for FY25.”

After the announcement, the Aurobindo Pharma stock gained as much as 2.8% in early trade on Monday to hit a fresh 52-week high of ₹1,490 apiece on the NSE. However, shares of Aurobindo Pharma soon trimmed gains to trade nearly lower at ₹1,447.8, down 0.13%, by 12:30 pm. The stock has jumped over 10% this month and is up more than 35% year-to-date.